Stealth BioTherapeutics Corp. ADS
MITO
MITO was delisted on the 15th of November, 2022.
12 hedge funds and large institutions have $1.53M invested in Stealth BioTherapeutics Corp. ADS in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 5 closing their positions.
8% less funds holding
Funds holding: 13 → 12 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
61% less capital invested
Capital invested by funds: $3.9M → $1.53M (-$2.37M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$123K |
| 2 |
Two Sigma Advisers
New York
|
+$31.7K |
| 3 |
SBL
Sargent Bickham Lagudis
Boulder,
Colorado
|
+$20.5K |
| 4 |
PAM
PVG Asset Management
Golden,
Colorado
|
+$16.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$14.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.12M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$473K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$419K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$177K |
| 5 |
Squarepoint
New York
|
-$100K |
MITO Hedge Fund Activity: Q2 2021 in Review
12 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Stealth BioTherapeutics Corp. ADS (MITO) for Q2 2021, worth a combined $1.53M — down 61% from $3.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of MITO and 4 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 2 added.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $123K. The largest seller was Renaissance Technologies, cutting an estimated $1.12M.
- 12 institutional investors held Stealth BioTherapeutics Corp. ADS (MITO) as of Q2 2021, down from 13 in Q1 2021.
- Funds reported $1.53M of Stealth BioTherapeutics Corp. ADS stock for Q2 2021, down 61% quarter-over-quarter.
- 4 funds opened new Stealth BioTherapeutics Corp. ADS positions in Q2 2021 and 5 closed out, a net change of -1 holder.
- The largest Stealth BioTherapeutics Corp. ADS buyer in Q2 2021 was Goldman Sachs, an estimated $123K added.
- The largest Stealth BioTherapeutics Corp. ADS seller in Q2 2021 was Renaissance Technologies, an estimated $1.12M sold.
Based on aggregated 13F filings for Q2 2021.